Mereletinib

INN name:	Mereletinib
Lab codes:	AZD-9291
Chemical name:	N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
Molecular formula:	C28H33N7O2
Chemical Structure:	Add caption
CAS Registry Number:	1421373-65-0
Originator:	AstraZeneca
Class:	Antineoplastic
Mechanism of Action:	Epidermal growth factor inhibitors
WHO ATC code:	L01
EPhMRA code:	L1
Clinical Trials:
Conditions Phases Interventions Recruitment Locally Advanced or Metastatic Non-small Cell Lung Cancer Phase 3 Combination Recruiting Locally Advanced or Metastatic EGFR T790M+ NSCLC Phase 3 Combination Recruiting Lung Cancer Phase 3 Alone Not yet recruiting Stage IB-IIIA Non-small Cell Lung Carcinoma, With a Centrally Confirmed, Common Sensitising EGFR Mutations Phase 3 Combination Not yet recruiting Advanced Refractory Solid Tumors or Lymphomas Phase 2 Combination Recruiting Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) Phase 2 Combination Active, not recruiting Lung Cancer|Targeted Therapy Phase 2 Alone Recruiting Non Small Cell Lung Cancer Phase 2 Alone Active, not recruiting Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer Phase 1|Phase 2 Alone Active, not recruiting Advanced Non Small Cell Lung Cancer Phase 1 Combination Recruiting Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer Phase 1 Combination Active, not recruiting Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive Phase 1 Alone Not yet recruiting Stage IV or Recurrent Non-small Cell Lung Cancer Phase 1 Alone Not yet recruiting EGFR Mutation Positive Advanced Non Small Cell Lung Cancer Phase 1 Combination Recruiting Non Small Cell Lung Cancer Phase 1 Combination Active, not recruiting Advanced or Metastatic Non-small Cell Lung Cancer Phase 1 Combination Not yet recruiting Solid Tumours Phase 1 Combination Recruiting EGFR T790M Mutation Positive NSCLC Alone Available
Recent activities on the drug: